Full metadata record

DC Field Value Language
dc.contributor.authorLee, Young-Ho-
dc.contributor.authorYoon, Hong Yeol-
dc.contributor.authorShin, Jung Min-
dc.contributor.authorSaravanakumar, G.-
dc.contributor.authorNoh, Kyung Hee-
dc.contributor.authorSong, Kwon-Ho-
dc.contributor.authorJeon, Ju-Hong-
dc.contributor.authorKim, Dong-Wan-
dc.contributor.authorLee, Kyung-Mi-
dc.contributor.authorKim, Kwangmeyung-
dc.contributor.authorKwon, Ick Chan-
dc.contributor.authorPark, Jae Hyung-
dc.contributor.authorKim, Tae Woo-
dc.date.accessioned2024-01-20T07:34:20Z-
dc.date.available2024-01-20T07:34:20Z-
dc.date.created2021-09-05-
dc.date.issued2015-02-10-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/125768-
dc.description.abstractAntigen-specific CD8(+) cytotoxic T lymphocytes (CTLs) are key elements of immunological rejection in transplantation as well as cancer immunotherapy. Most tumors, however, are not immunologically rejected because they have self antigens, which are not recognized as the foreigner by CTLs. In this study, we hypothesized that "foreignizing" tumor cells by delivering non-self foreign antigens into the tumors would result in rejection by foreign antigen-reactive CTLs. As the model system to foreignize the tumors, we prepared a polymeric conjugate consisting of hyaluronic acid as the CD44(+) tumor-targeting ligand and ovalbumin (OVA) as a foreign antigen. When the conjugate was treated with CD44(high) TC-1 tumor cells, it was effectively taken up and allowed for displaying of antigenic OVA(257-264) peptide at MHC class I on the surface of the cells. In addition, the conjugate was effectively accumulated into tumor tissue after its systemic administration to mice which are immunized with a vaccine for a vaccinia virus expressing OVA to generate OVA(257-264) specific CTLs, resulting in substantial inhibition of tumor growth. Overall, these results suggest that the polymeric conjugates bearing foreign antigens may be innovative and promising cancer immunotherapeutic agents by foreignizing tumor cells, leading to immunological rejection. (C) 2014 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.titleA polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2014.12.007-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF CONTROLLED RELEASE, v.199, pp.98 - 105-
dc.citation.titleJOURNAL OF CONTROLLED RELEASE-
dc.citation.volume199-
dc.citation.startPage98-
dc.citation.endPage105-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000348456800011-
dc.identifier.scopusid2-s2.0-84949114933-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordAuthorPolymeric conjugate-
dc.subject.keywordAuthorCancer immunotherapy-
dc.subject.keywordAuthorAntigen delivery-
dc.subject.keywordAuthorHyaluronic acid-
dc.subject.keywordAuthorForeignization-
Appears in Collections:
KIST Article > 2015
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE